Kukje Pharma Co., Ltd. (002720.KS)
KRW 4970.0
(-2.17%)
KRW 4970.0
(-2.17%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 135.37 Billion KRW | 6.94% |
| 2022 | 126.58 Billion KRW | 5.71% |
| 2021 | 119.74 Billion KRW | -8.17% |
| 2020 | 130.39 Billion KRW | 17.34% |
| 2019 | 111.12 Billion KRW | 3.2% |
| 2018 | 107.68 Billion KRW | -12.67% |
| 2017 | 123.31 Billion KRW | 2.18% |
| 2016 | 120.68 Billion KRW | 2.59% |
| 2015 | 117.63 Billion KRW | -3.91% |
| 2014 | 122.42 Billion KRW | 1.63% |
| 2013 | 120.46 Billion KRW | -4.98% |
| 2012 | 126.76 Billion KRW | 20.9% |
| 2011 | 104.85 Billion KRW | -20.14% |
| 2010 | 131.3 Billion KRW | 7.13% |
| 2009 | 122.56 Billion KRW | 0.76% |
| 2008 | 121.63 Billion KRW | 17.23% |
| 2007 | 103.75 Billion KRW | 6.67% |
| 2006 | 97.27 Billion KRW | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 37.53 Billion KRW | 6.34% |
| 2024 Q2 | 37.64 Billion KRW | 0.29% |
| 2023 Q1 | 32.4 Billion KRW | 4.78% |
| 2023 Q4 | 35.29 Billion KRW | 9.88% |
| 2023 FY | 135.37 Billion KRW | 6.94% |
| 2023 Q3 | 32.12 Billion KRW | -9.62% |
| 2023 Q2 | 35.54 Billion KRW | 9.68% |
| 2022 FY | 126.58 Billion KRW | 5.71% |
| 2022 Q1 | 33.25 Billion KRW | 1.06% |
| 2022 Q4 | 30.92 Billion KRW | 2.54% |
| 2022 Q2 | 32.24 Billion KRW | -3.04% |
| 2022 Q3 | 30.16 Billion KRW | -6.45% |
| 2021 Q1 | 27.38 Billion KRW | -3.05% |
| 2021 Q2 | 29.62 Billion KRW | 8.19% |
| 2021 Q3 | 29.83 Billion KRW | 0.7% |
| 2021 Q4 | 32.9 Billion KRW | 10.28% |
| 2021 FY | 119.74 Billion KRW | -8.17% |
| 2020 Q3 | 33.49 Billion KRW | -5.96% |
| 2020 Q2 | 35.61 Billion KRW | 7.81% |
| 2020 FY | 130.39 Billion KRW | 17.34% |
| 2020 Q1 | 33.03 Billion KRW | 12.42% |
| 2020 Q4 | 28.24 Billion KRW | -15.67% |
| 2019 Q3 | 26.07 Billion KRW | -9.44% |
| 2019 FY | 111.12 Billion KRW | 3.2% |
| 2019 Q1 | 26.85 Billion KRW | 33.46% |
| 2019 Q2 | 28.79 Billion KRW | 7.24% |
| 2019 Q4 | 29.38 Billion KRW | 12.68% |
| 2018 FY | 107.68 Billion KRW | -12.67% |
| 2018 Q4 | 20.12 Billion KRW | -27.4% |
| 2018 Q3 | 27.71 Billion KRW | -6.94% |
| 2018 Q2 | 29.78 Billion KRW | -0.92% |
| 2018 Q1 | 30.05 Billion KRW | 0.41% |
| 2017 Q4 | 29.93 Billion KRW | -8.74% |
| 2017 Q1 | 29.4 Billion KRW | 2.22% |
| 2017 FY | 123.31 Billion KRW | 2.18% |
| 2017 Q2 | 31.17 Billion KRW | 6.01% |
| 2017 Q3 | 32.8 Billion KRW | 5.23% |
| 2016 Q4 | 28.76 Billion KRW | -3.73% |
| 2016 Q1 | 29.55 Billion KRW | 3.39% |
| 2016 Q2 | 32.48 Billion KRW | 9.91% |
| 2016 Q3 | 29.87 Billion KRW | -8.03% |
| 2016 FY | 120.68 Billion KRW | 2.59% |
| 2015 Q3 | 26.7 Billion KRW | -16.32% |
| 2015 Q4 | 28.58 Billion KRW | 7.06% |
| 2015 FY | 117.63 Billion KRW | -3.91% |
| 2015 Q1 | 30.44 Billion KRW | 0.86% |
| 2015 Q2 | 31.9 Billion KRW | 4.82% |
| 2014 Q1 | 29.83 Billion KRW | -3.83% |
| 2014 Q4 | 30.18 Billion KRW | -3.33% |
| 2014 Q3 | 31.22 Billion KRW | 0.1% |
| 2014 Q2 | 31.19 Billion KRW | 4.56% |
| 2014 FY | 122.42 Billion KRW | 1.63% |
| 2013 Q1 | 29.82 Billion KRW | 21.66% |
| 2013 FY | 120.46 Billion KRW | -4.98% |
| 2013 Q3 | 29.49 Billion KRW | -2.08% |
| 2013 Q4 | 31.01 Billion KRW | 5.16% |
| 2013 Q2 | 30.12 Billion KRW | 0.98% |
| 2012 Q4 | 24.51 Billion KRW | -21.83% |
| 2012 FY | 126.76 Billion KRW | 20.9% |
| 2012 Q2 | 32.45 Billion KRW | -12.67% |
| 2012 Q3 | 31.36 Billion KRW | -3.34% |
| 2012 Q1 | 37.15 Billion KRW | 0.0% |
| 2011 Q3 | 33.81 Billion KRW | 15.91% |
| 2011 Q1 | 31.14 Billion KRW | -11.15% |
| 2011 Q2 | 29.17 Billion KRW | -6.32% |
| 2011 FY | 104.85 Billion KRW | -20.14% |
| 2010 Q4 | 35.05 Billion KRW | 7.24% |
| 2010 FY | 131.3 Billion KRW | 7.13% |
| 2010 Q1 | 29.13 Billion KRW | -7.12% |
| 2010 Q2 | 32.43 Billion KRW | 11.3% |
| 2010 Q3 | 32.68 Billion KRW | 0.79% |
| 2009 Q2 | 29.94 Billion KRW | 6.1% |
| 2009 Q3 | 32.11 Billion KRW | 7.22% |
| 2009 Q4 | 31.37 Billion KRW | -2.3% |
| 2009 FY | 122.56 Billion KRW | 0.76% |
| 2009 Q1 | 28.22 Billion KRW | -10.59% |
| 2008 Q3 | 30.81 Billion KRW | -0.66% |
| 2008 FY | 121.63 Billion KRW | 17.23% |
| 2008 Q2 | 31.02 Billion KRW | 21.61% |
| 2008 Q4 | 31.56 Billion KRW | 2.43% |
| 2008 Q1 | 25.51 Billion KRW | -0.59% |
| 2007 Q3 | 26.4 Billion KRW | 0.89% |
| 2007 FY | 103.75 Billion KRW | 6.67% |
| 2007 Q2 | 26.17 Billion KRW | 0.0% |
| 2007 Q4 | 25.66 Billion KRW | -2.83% |
| 2006 FY | 97.27 Billion KRW | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 1.339% |
| Dong-A Socio Holdings Co., Ltd. | 1132 Billion KRW | 88.041% |
| Ildong Holdings Co., Ltd. | 638.44 Billion KRW | 78.797% |
| HANDOK Inc. | 522.74 Billion KRW | 74.103% |
| Yuhan Corporation | 1858.98 Billion KRW | 92.718% |
| Dong-A ST Co., Ltd. | 663.98 Billion KRW | 79.612% |
| SAMSUNG PHARM. Co., LTD. | 51.95 Billion KRW | -160.557% |
| Hanmi Pharm. Co., Ltd. | 1490.88 Billion KRW | 90.92% |
| Hanall Biopharma Co.,Ltd | 134.9 Billion KRW | -0.343% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 63.466% |
| Dong Sung Bio Pharm.Co.,Ltd. | 88.59 Billion KRW | -52.802% |
| MYUNGMOON Pharm co.,Ltd | 169.56 Billion KRW | 20.166% |
| Hana Pharm Co., Ltd. | 224.45 Billion KRW | 39.689% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 1.339% |
| Ilsung Pharmaceuticals Co., Ltd. | 78.05 Billion KRW | -73.436% |
| REYON Pharmaceutical Co., Ltd. | 151.07 Billion KRW | 10.391% |
| Aprogen pharmaceuticals,Inc. | 87.36 Billion KRW | -54.953% |
| JW Holdings Corporation | 928.07 Billion KRW | 85.414% |
| Ildong Pharmaceutical Co., Ltd. | 600.75 Billion KRW | 77.466% |
| Chong Kun Dang Pharmaceutical Corp. | 1669.4 Billion KRW | 91.891% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.915% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 32.391% |
| Hyundai Pharmaceutical Co., Ltd. | 180.76 Billion KRW | 25.11% |
| Samil Pharmaceutical Co.,Ltd | 196.34 Billion KRW | 31.054% |
| Jeil Pharmaceutical Co.,Ltd | 726.39 Billion KRW | 81.364% |
| Yuyu Pharma, Inc. | 137.2 Billion KRW | 1.339% |
| Kwang Dong Pharmaceutical Co., Ltd. | 1514.45 Billion KRW | 91.061% |
| Daewoong pharmaceutical Co.,Ltd | 1375.32 Billion KRW | 90.157% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.915% |
| Yuhan Corporation | 1858.98 Billion KRW | 92.718% |
| Jeil Pharma Holdings Inc | 794.71 Billion KRW | 82.966% |
| Yungjin Pharm. Co., Ltd. | 234.9 Billion KRW | 42.371% |
| Suheung Co., Ltd. | 594.56 Billion KRW | 77.232% |
| JW Pharmaceutical Corporation | 748.52 Billion KRW | 81.915% |
| Samjin Pharmaceuticals Co., Ltd. | 292.12 Billion KRW | 53.66% |
| Korea United Pharm Inc. | 278.94 Billion KRW | 51.469% |
| CKD Bio Corp. | 160.35 Billion KRW | 15.578% |
| Daewon Pharmaceutical Co., Ltd. | 526.95 Billion KRW | 74.31% |
| Dongwha Pharm.Co.,Ltd | 361.1 Billion KRW | 62.512% |
| Whan In Pharm Co.,Ltd. | 230.39 Billion KRW | 41.243% |
| Shin Poong Pharm.Co.,Ltd. | 200.22 Billion KRW | 32.391% |
| Chong Kun Dang Holdings Corp. | 879.78 Billion KRW | 84.613% |
| Boryung Corporation | 859.62 Billion KRW | 84.252% |
| Bukwang Pharmaceutical Co., Ltd. | 125.92 Billion KRW | -7.5% |
| Ilyang Pharmaceutical Co.,Ltd | 370.53 Billion KRW | 63.466% |
| JW Lifescience Corporation | 206.86 Billion KRW | 34.558% |